MBG453

TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial

What's the purpose of the trial?

This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS). The name of the study drug involved in this study is MBG453.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
20
Last Updated
1 month ago
Patient Screener

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There are 3 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Sabatolimab is a kind of drug called a TIM-3 monoclonal antibody that targets the TIM-3 protein found on the surface of several different types of cells in the immune system.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

MBG453

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.